Chronic Kidney Disease (CKD) Stage 5 Clinical Trial
Official title:
Effect of Pre-emptive Assessment of Self-care Peritoneal Dialysis (PD) Ability on PD Choice in Patients With Stage 5 Chronic Kidney Disease
Peritoneal dialysis is an effective renal replacement therapy with higher quality of life and lower treatment cost than hemodialysis.However, the application rate of peritoneal dialysis is much lower than that of hemodialysis. One of the reasons is that patients need to complete fluid changing operation independently, which is especially challenging for elderly and frail patients. Assisted peritoneal dialysis can help patients with independent dialysis disorders to complete dialysis. Currently, there is a lack of standard tools to assess patients' ability to conduct independent dialysis and to determine whether assisted dialysis is needed. Moreover, routine assessment is arranged after the training of dialysis operation, which leads to some patients giving up the procedure at an early stage, resulting in a low selection rate of the procedure.The purpose of this study was to investigate the effect of using a standard scale to evaluate the ability to perform abdominal dialysis in patients with stage 5 chronic kidney disease (CKD) before deciding on dialysis modality.
Status | Not yet recruiting |
Enrollment | 232 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age >=18 years old; 2. Need dialysis within 6 months; 3. Informed consent. Exclusion Criteria: 1. Absolute PD contraindications; 2. Need urgent dialysis; 3. RTX as initial renal replacement therapy. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Jiao Tong University School of Medicine |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The rate of PD choice | up to 90 days | ||
Secondary | The aPD utilization rate | up to 180 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00616902 -
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
|
Phase 3 | |
Recruiting |
NCT05465044 -
Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)
|
N/A |